EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$37.85
+0.45%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$38.96
From 52W high−21.72%
Volume330831.00
Market cap$4.11B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$38.96
From 52W high
−21.72%
Volume
330831.00
Market cap
$4.11B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−18.7x
P/E (TTM)
—
RSI (14)
42.7
MomentumView details →
1D Return
+0.45%
YTD Return
+53.20%
SummaryUpdated Jun 1, 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. The company went public in March 2021 and focuses on developing innovative small molecule therapies to treat rare musculoskeletal diseases. Edgewise specializes in precision medicine approaches targeting genetically defined muscle disorders, with their lead drug candidate currently in clinical development for treating devastating muscle-wasting diseases including Duchenne muscular dystrophy.
Similar companies
Latest newsMore news →
Servier reported that sevasemten failed to slow Becker muscular dystrophy in the Phase 3 GRAND CANYON study.22h agoEdgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.27d agoEdgewise Therapeutics unveiled the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain and improved cardiac relaxation while preserving systolic function in preclinical models.43d ago